Cargando…
Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey
Icatibant is used to treat acute hereditary angioedema with C1 inhibitor deficiency types I/II (C1‐INH‐HAE types I/II) and has shown promise in angioedema due to acquired C1 inhibitor deficiency (C1‐INH‐AAE). Data from the Icatibant Outcome Survey (IOS) were analysed to evaluate the effectiveness of...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343339/ https://www.ncbi.nlm.nih.gov/pubmed/27936514 http://dx.doi.org/10.1111/cei.12910 |
_version_ | 1782513348631330816 |
---|---|
author | Longhurst, H. J. Zanichelli, A. Caballero, T. Bouillet, L. Aberer, W. Maurer, M. Fain, O. Fabien, V. Andresen, I. |
author_facet | Longhurst, H. J. Zanichelli, A. Caballero, T. Bouillet, L. Aberer, W. Maurer, M. Fain, O. Fabien, V. Andresen, I. |
author_sort | Longhurst, H. J. |
collection | PubMed |
description | Icatibant is used to treat acute hereditary angioedema with C1 inhibitor deficiency types I/II (C1‐INH‐HAE types I/II) and has shown promise in angioedema due to acquired C1 inhibitor deficiency (C1‐INH‐AAE). Data from the Icatibant Outcome Survey (IOS) were analysed to evaluate the effectiveness of icatibant in the treatment of patients with C1‐INH‐AAE and compare disease characteristics with those with C1‐INH‐HAE types I/II. Key medical history (including prior occurrence of attacks) was recorded upon IOS enrolment. Thereafter, data were recorded retrospectively at approximately 6‐month intervals during patient follow‐up visits. In the icatibant‐treated population, 16 patients with C1‐INH‐AAE had 287 attacks and 415 patients with C1‐INH‐HAE types I/II had 2245 attacks. Patients with C1‐INH‐AAE versus C1‐INH‐HAE types I/II were more often male (69 versus 42%; P = 0·035) and had a significantly later mean (95% confidence interval) age of symptom onset [57·9 (51·33–64·53) versus 14·0 (12·70–15·26) years]. Time from symptom onset to diagnosis was significantly shorter in patients with C1‐INH‐AAE versus C1‐INH‐HAE types I/II (mean 12·3 months versus 118·1 months; P = 0·006). Patients with C1‐INH‐AAE showed a trend for higher occurrence of attacks involving the face (35 versus 21% of attacks; P = 0·064). Overall, angioedema attacks were more severe in patients with C1‐INH‐HAE types I/II versus C1‐INH‐AAE (61 versus 40% of attacks were classified as severe to very severe; P < 0·001). Median total attack duration was 5·0 h and 9·0 h for patients with C1‐INH‐AAE versus C1‐INH‐HAE types I/II, respectively. |
format | Online Article Text |
id | pubmed-5343339 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-53433392017-03-10 Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey Longhurst, H. J. Zanichelli, A. Caballero, T. Bouillet, L. Aberer, W. Maurer, M. Fain, O. Fabien, V. Andresen, I. Clin Exp Immunol Original Articles Icatibant is used to treat acute hereditary angioedema with C1 inhibitor deficiency types I/II (C1‐INH‐HAE types I/II) and has shown promise in angioedema due to acquired C1 inhibitor deficiency (C1‐INH‐AAE). Data from the Icatibant Outcome Survey (IOS) were analysed to evaluate the effectiveness of icatibant in the treatment of patients with C1‐INH‐AAE and compare disease characteristics with those with C1‐INH‐HAE types I/II. Key medical history (including prior occurrence of attacks) was recorded upon IOS enrolment. Thereafter, data were recorded retrospectively at approximately 6‐month intervals during patient follow‐up visits. In the icatibant‐treated population, 16 patients with C1‐INH‐AAE had 287 attacks and 415 patients with C1‐INH‐HAE types I/II had 2245 attacks. Patients with C1‐INH‐AAE versus C1‐INH‐HAE types I/II were more often male (69 versus 42%; P = 0·035) and had a significantly later mean (95% confidence interval) age of symptom onset [57·9 (51·33–64·53) versus 14·0 (12·70–15·26) years]. Time from symptom onset to diagnosis was significantly shorter in patients with C1‐INH‐AAE versus C1‐INH‐HAE types I/II (mean 12·3 months versus 118·1 months; P = 0·006). Patients with C1‐INH‐AAE showed a trend for higher occurrence of attacks involving the face (35 versus 21% of attacks; P = 0·064). Overall, angioedema attacks were more severe in patients with C1‐INH‐HAE types I/II versus C1‐INH‐AAE (61 versus 40% of attacks were classified as severe to very severe; P < 0·001). Median total attack duration was 5·0 h and 9·0 h for patients with C1‐INH‐AAE versus C1‐INH‐HAE types I/II, respectively. John Wiley and Sons Inc. 2017-02-09 2017-04 /pmc/articles/PMC5343339/ /pubmed/27936514 http://dx.doi.org/10.1111/cei.12910 Text en © 2016 British Society for Immunology Open access. |
spellingShingle | Original Articles Longhurst, H. J. Zanichelli, A. Caballero, T. Bouillet, L. Aberer, W. Maurer, M. Fain, O. Fabien, V. Andresen, I. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey |
title | Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey |
title_full | Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey |
title_fullStr | Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey |
title_full_unstemmed | Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey |
title_short | Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey |
title_sort | comparing acquired angioedema with hereditary angioedema (types i/ii): findings from the icatibant outcome survey |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343339/ https://www.ncbi.nlm.nih.gov/pubmed/27936514 http://dx.doi.org/10.1111/cei.12910 |
work_keys_str_mv | AT longhursthj comparingacquiredangioedemawithhereditaryangioedematypesiiifindingsfromtheicatibantoutcomesurvey AT zanichellia comparingacquiredangioedemawithhereditaryangioedematypesiiifindingsfromtheicatibantoutcomesurvey AT caballerot comparingacquiredangioedemawithhereditaryangioedematypesiiifindingsfromtheicatibantoutcomesurvey AT bouilletl comparingacquiredangioedemawithhereditaryangioedematypesiiifindingsfromtheicatibantoutcomesurvey AT abererw comparingacquiredangioedemawithhereditaryangioedematypesiiifindingsfromtheicatibantoutcomesurvey AT maurerm comparingacquiredangioedemawithhereditaryangioedematypesiiifindingsfromtheicatibantoutcomesurvey AT faino comparingacquiredangioedemawithhereditaryangioedematypesiiifindingsfromtheicatibantoutcomesurvey AT fabienv comparingacquiredangioedemawithhereditaryangioedematypesiiifindingsfromtheicatibantoutcomesurvey AT andreseni comparingacquiredangioedemawithhereditaryangioedematypesiiifindingsfromtheicatibantoutcomesurvey AT comparingacquiredangioedemawithhereditaryangioedematypesiiifindingsfromtheicatibantoutcomesurvey |